Switch theme
Sign up to access all valuation multiples
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
1998
253
LTM Revenue $319M
LTM EBITDA $101M
$588M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ironwood Pharmaceuticals has a last 12-month revenue (LTM) of $319M and a last 12-month EBITDA of $101M.
In the most recent fiscal year, Ironwood Pharmaceuticals achieved revenue of $351M and an EBITDA of $100M.
Ironwood Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ironwood Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $319M | XXX | $351M | XXX | XXX | XXX |
| Gross Profit | $319M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $101M | XXX | $100M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $75.2M | XXX | $95.7M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $7.4M | XXX | $0.9M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $495M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ironwood Pharmaceuticals's stock price is $1.
Ironwood Pharmaceuticals has current market cap of $97.0M, and EV of $588M.
See Ironwood Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $588M | $97.0M | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ironwood Pharmaceuticals has market cap of $97.0M and EV of $588M.
Ironwood Pharmaceuticals's trades at 1.7x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Ironwood Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ironwood Pharmaceuticals has a P/E ratio of 13.2x.
See valuation multiples for Ironwood Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $97.0M | XXX | $97.0M | XXX | XXX | XXX |
| EV (current) | $588M | XXX | $588M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.8x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 7.8x | XXX | 6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.2x | XXX | 110.2x | XXX | XXX | XXX |
| EV/FCF | 8.5x | XXX | 5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIronwood Pharmaceuticals's last 12 month revenue growth is -16%
Ironwood Pharmaceuticals's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.0M for the same period.
Ironwood Pharmaceuticals's rule of 40 is -225% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ironwood Pharmaceuticals's rule of X is -9% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ironwood Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -16% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -225% | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -9% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ironwood Pharmaceuticals acquired XXX companies to date.
Last acquisition by Ironwood Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Ironwood Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ironwood Pharmaceuticals founded? | Ironwood Pharmaceuticals was founded in 1998. |
| Where is Ironwood Pharmaceuticals headquartered? | Ironwood Pharmaceuticals is headquartered in United States of America. |
| How many employees does Ironwood Pharmaceuticals have? | As of today, Ironwood Pharmaceuticals has 253 employees. |
| Who is the CEO of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's CEO is Mr. Thomas A. McCourt. |
| Is Ironwood Pharmaceuticals publicy listed? | Yes, Ironwood Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals trades under IRWD ticker. |
| When did Ironwood Pharmaceuticals go public? | Ironwood Pharmaceuticals went public in 2010. |
| Who are competitors of Ironwood Pharmaceuticals? | Similar companies to Ironwood Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's current market cap is $97.0M |
| What is the current revenue of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's last 12 months revenue is $319M. |
| What is the current revenue growth of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals revenue growth (NTM/LTM) is -16%. |
| What is the current EV/Revenue multiple of Ironwood Pharmaceuticals? | Current revenue multiple of Ironwood Pharmaceuticals is 1.8x. |
| Is Ironwood Pharmaceuticals profitable? | Yes, Ironwood Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's last 12 months EBITDA is $101M. |
| What is Ironwood Pharmaceuticals's EBITDA margin? | Ironwood Pharmaceuticals's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Ironwood Pharmaceuticals? | Current EBITDA multiple of Ironwood Pharmaceuticals is 5.8x. |
| What is the current FCF of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's last 12 months FCF is $69.3M. |
| What is Ironwood Pharmaceuticals's FCF margin? | Ironwood Pharmaceuticals's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Ironwood Pharmaceuticals? | Current FCF multiple of Ironwood Pharmaceuticals is 8.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
